Evidence map›Paper›PMID 28447936›Full record

ArticleeLife2017

PPP1R15A-mediated dephosphorylation of eIF2α is unaffected by Sephin1 or Guanabenz.

Ana Crespillo-Casado, Joseph E Chambers, Peter M Fischer, Stefan J Marciniak, David Ron

Open access · goldAbstract read
In one paragraph

Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Evolutionarily conserved inhibitory uORFs sensitizeProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ana Crespillo-CasadoCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-7230-3188
Joseph E ChambersCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-4675-0053
Peter M FischerDivision of Biomolecular Science and Medicinal Chemistry, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.ORCID 0000-0002-5866-9271
Stefan J MarciniakCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8472-7183
David RonCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-3014-5636
University of Cambridge · GBUniversity of Nottingham · GB

Funding

Medical Research Council G0601840Medical Research Council G1002610Wellcome Trust
6 · The paper itself

Abstract

Dephosphorylation of translation initiation factor 2 (eIF2α) terminates signalling in the mammalian integrated stress response (ISR) and has emerged as a promising target for modifying the course of protein misfolding diseases. The [(

Indexed as

Protein Processing, Post-TranslationalEnzyme InhibitorsEukaryotic Initiation Factor-2GuanabenzProtein Phosphatase 1Enzyme InhibitorsEukaryotic Initiation Factor-2GuanabenzPPP1R15A protein, humanProtein Phosphatase 1sephin1biochemistrycell biologychemical biologyCricetulus griseusdrug actionhumanphosphorylationprotein synthesis

Identifiers

PMID28447936
PMCPMC5429092
OpenAlexW2609435610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.